Adult Vaccines Market Size by Vaccine Type, End-Users, project the Adult Vaccines, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
Global Adult Vaccines Market is expected to reach US$ 34.11 Bn by 2032 from US$ 19.45 Bn in 2025, at a CAGR of 8.36% during the forecast period.
Global Adult Vaccines Market Overview:
Vaccines are biological preparations that are administered in an individual’s body to establish immunity to a particular disease. Adult’s immunity deteriorates over time, putting them at risk of contracting new infectious diseases. The vaccine contains some part of the disease-causing agent, which is either weakened or killed to the point that it cannot cause harm to the human body.
Global Adult Vaccines Market Dynamics:
The increasing prevalence of contagious diseases globally is the major factor driving the market growth.
Growing occurrences of contagious diseases such as influenza, hepatitis, zoster etc. and initiatives undertaken by the government to spread awareness about the importance of vaccination are the primary factors that encourage the adult vaccines market growth. In addition, the government's increasing partnerships with pharma and biopharma companies to develop novel vaccines would benefit the adult vaccines industry's growth in the forecast years.
Apart from the government, non-governmental organisations are also now educating and encouraging adults to get vaccinations. During the forecast period, the presence of several NGOs is expected to be a driving factor in rising demand for adult vaccines in the global adult vaccines market. The WHO and UNICEF have issued recommendations on implementing a national immunisation programme in order to ensure that everyone in the world is vaccinated.
All of these recent trends are expected to boost the global adult vaccines market. In recent times, there is an upsurge in infectious diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Ebola virus, Zika virus and others, which has increased the demand for the administration of vaccine worldwide.
However, certain factors like high healthcare expenditure, lack of skilled professionals and stringent government regulations may restrain the adult vaccine market from growing. Along with this, limited production of vaccine and various side-effects associated with the vaccine such as muscular aches and fever may impact negatively the market growth.
The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Global Adult Vaccines Market Segment Analysis:
The global Adult Vaccines Market is segmented on the basis of vaccine type, application and end-users.
Based on Vaccine Type, the inactivated vaccine segment is expected to dominate the global market during forecast years. The increasing awareness of people about the advantages of vaccination is expected to aid the segment growth. Other features of inactivated vaccines such as long shelf life and high stability also contribute to the segment growth.
In comparison to other conventional vaccines, the DNA vaccine is expected to develop at the fastest rate over the forecast period, owing to its high specificity and lower risk of introduction into the genome.
Based on Application, the influenza segment holds a dominant market share. The segment dominance is attributed to the rising prevalence of various infections caused by the influenza virus such as acute respiratory syndrome, sinus problems, pneumonia and others. In the United States alone, influenza causes 36,000 annual deaths, and the total number of hospitalizations associated with influenza is estimated to be 226,000. The live influenza vaccines tend to be equivalent to TIVs in terms of preventive efficacy (trivalent, inactivated influenza vaccines.)
To know about the Research Methodology :- Request Free Sample Report
Global Adult Vaccines Market Regional Insights:
North America is expected to account for the dominant market share over the forecast period, followed by Europe.
Due to the presence of advanced healthcare infrastructure, Europe and North America dominate the global adult vaccines market. In North America, U.S. holds the major market share. Owing to the high prevalence of infectious diseases, increasing investments from the government, ongoing R&D activities and advancements in the development of novel vaccines boost the adult vaccines market in these regions.
The Asia Pacific is expected to witness the fastest growth during the forecast period.
Owing to rising vaccination awareness and increased immunisation initiatives, Asia-Pacific offers lucrative opportunities for the global Adult Vaccines market. Other factors contributing to the market growth in the region are the increase in vaccine demand, rise in geriatric population, increased awareness and continued government support for vaccine development.
The report also helps in understanding the Global Adult Vaccines Market dynamics, structure by analyzing the market segments and project the Global Adult Vaccines Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Adult Vaccines Market make the report investor’s guide.
Global Adult Vaccines Market, Key Developments:
In June 2025, Merck initiated the Phase 3 MOBILIZE-1 clinical trial to evaluate the efficacy, safety, and immunogenic response of V181, its single-dose dengue vaccine candidate. The study is focused on adults aged 18 years and older.
Global Adult Vaccines Market Scope: Inquire before buying
| Global Adult Vaccines Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 19.45 USD Billion |
| Forecast Period 2026-2032 CAGR: | 8.36% | Market Size in 2032: | 34.12 USD Billion |
| Segments Covered: | by Vaccine Type | Inactivated Attenuated Toxoid Subunit DNA Vaccines Others |
|
| by Application | Influenza Tetanus/Diphtheria/Pertussis Human Papillomavirus Zoster Pneumococcal Hepatitis |
||
| by Age Group | 18–30 years 31–50 years 51–65 years Above 65 years |
||
| by End-Users | Healthcare Firms Hospital Others |
||
Global Adult Vaccines Market, by Region
• North America
• Europe
• South America
• MEA
• APAC
Global Adult Vaccines Market, Key Players
1. GlaxoSmithKline plc (GSK)
2. Merck & Co., Inc. (MSD)
3. Sanofi (Sanofi Pasteur)
4. Pfizer Inc.
5. CSL Limited (CSL Seqirus)
6. Johnson & Johnson (Janssen)
7. AstraZeneca plc
8. Moderna, Inc.
9. BioNTech SE
10. Takeda Pharmaceutical Company Limited
11. Serum Institute of India Pvt. Ltd.
12. Novavax, Inc.
13. Bavarian Nordic A/SDynavax Technologies Corporation
14. Emergent BioSolutions Inc.
15. Valneva SE
16. Sinovac Biotech Ltd.
17. Sinopharm / China National Biotec Group (CNBG)
18. Biological E Limited
19. Panacea Biotec Ltd.
20. Bharat Biotech International Limited
21. Shenzhen Kangtai Biological Products Co., Ltd.
22. Beijing Tiantan Biological Products Co., Ltd.
23. Chengdu Institute of Biological Products Co., Ltd.
24. Hualan Biological Engineering Inc.
25. Daiichi Sankyo Company, Limited
26. Inovio Pharmaceuticals, Inc.
27. SK bioscience Co., Ltd.
28. CureVac N.V.
29. Mitsubishi Tanabe Pharma Corporation